Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Marimed (MRMD) over the last 14 years, with Q3 2025 value amounting to $2.7 million.

  • Marimed's Cash from Operations rose 23325.03% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 6306.56%. This contributed to the annual value of $6.8 million for FY2024, which is 1422.25% down from last year.
  • According to the latest figures from Q3 2025, Marimed's Cash from Operations is $2.7 million, which was up 23325.03% from $297000.0 recorded in Q2 2025.
  • Marimed's 5-year Cash from Operations high stood at $10.8 million for Q2 2021, and its period low was -$6.3 million during Q2 2022.
  • For the 5-year period, Marimed's Cash from Operations averaged around $3.3 million, with its median value being $3.2 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 176025.96% in 2021, then plummeted by 15779.56% in 2022.
  • Over the past 5 years, Marimed's Cash from Operations (Quarter) stood at $7.6 million in 2021, then plummeted by 77.17% to $1.7 million in 2022, then soared by 86.18% to $3.2 million in 2023, then tumbled by 112.77% to -$413000.0 in 2024, then soared by 747.94% to $2.7 million in 2025.
  • Its Cash from Operations stands at $2.7 million for Q3 2025, versus $297000.0 for Q2 2025 and $1.3 million for Q1 2025.